User login
Answers to Clinical Questions in Primary Care Management of People with Obesity
Highlights From the 2016 AAN Annual Meeting
Click here to download the digital edition.
Click here to download the digital edition.
Click here to download the digital edition.
Essure<sup>®</sup>: Patient Education, Identification, and Counseling
Click here to download the PDF.
Female sterilization is the most widely used form of permanent birth control around the world, and for more than 3 decades, laparoscopic procedures have been the preferred intervention. This supplement covers a hysteroscopic sterilization option, which first became available in 2002.
Cindy M. Basinski, MD
Basinski and Juran, MDs, LLC
Newburgh, Indiana
Linda D. Bradley, MD
Cleveland Clinic
Cleveland, Ohio
Disclosures:
Dr. Basinski reports acting as a consultant for Bayer, including on Essure®.
Dr. Bradley reports acting as a consultant for Bayer, including on Essure®.
Click here to download the PDF.
Female sterilization is the most widely used form of permanent birth control around the world, and for more than 3 decades, laparoscopic procedures have been the preferred intervention. This supplement covers a hysteroscopic sterilization option, which first became available in 2002.
Cindy M. Basinski, MD
Basinski and Juran, MDs, LLC
Newburgh, Indiana
Linda D. Bradley, MD
Cleveland Clinic
Cleveland, Ohio
Disclosures:
Dr. Basinski reports acting as a consultant for Bayer, including on Essure®.
Dr. Bradley reports acting as a consultant for Bayer, including on Essure®.
Click here to download the PDF.
Female sterilization is the most widely used form of permanent birth control around the world, and for more than 3 decades, laparoscopic procedures have been the preferred intervention. This supplement covers a hysteroscopic sterilization option, which first became available in 2002.
Cindy M. Basinski, MD
Basinski and Juran, MDs, LLC
Newburgh, Indiana
Linda D. Bradley, MD
Cleveland Clinic
Cleveland, Ohio
Disclosures:
Dr. Basinski reports acting as a consultant for Bayer, including on Essure®.
Dr. Bradley reports acting as a consultant for Bayer, including on Essure®.
Diabetes Management Today: Issues in achieving glycemic goals
Supplement Editor:
M. Cecilia Lansang, MD, MPH
Contents
Diabetes management today: Issues in achieving glycemic goals
M. Cecilia Lansang
The role of hemoglobin A1c in the assessment of diabetes and cardiovascular risk
Courtney Nagel Sandler and Marie E. McDonnell
Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes
Om P. Ganda
Newer oral and noninsulin therapies to treat type 2 diabetes mellitus
Kathie L. Hermayer and Andrew Dake
New insulin preparations: A primer for the clinician
Luigi Meneghini
Inpatient hyperglycemia management: A practical review for primary medical and surgical teams
M. Cecilia Lansang and Guillermo E. Umpierrez
Supplement Editor:
M. Cecilia Lansang, MD, MPH
Contents
Diabetes management today: Issues in achieving glycemic goals
M. Cecilia Lansang
The role of hemoglobin A1c in the assessment of diabetes and cardiovascular risk
Courtney Nagel Sandler and Marie E. McDonnell
Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes
Om P. Ganda
Newer oral and noninsulin therapies to treat type 2 diabetes mellitus
Kathie L. Hermayer and Andrew Dake
New insulin preparations: A primer for the clinician
Luigi Meneghini
Inpatient hyperglycemia management: A practical review for primary medical and surgical teams
M. Cecilia Lansang and Guillermo E. Umpierrez
Supplement Editor:
M. Cecilia Lansang, MD, MPH
Contents
Diabetes management today: Issues in achieving glycemic goals
M. Cecilia Lansang
The role of hemoglobin A1c in the assessment of diabetes and cardiovascular risk
Courtney Nagel Sandler and Marie E. McDonnell
Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes
Om P. Ganda
Newer oral and noninsulin therapies to treat type 2 diabetes mellitus
Kathie L. Hermayer and Andrew Dake
New insulin preparations: A primer for the clinician
Luigi Meneghini
Inpatient hyperglycemia management: A practical review for primary medical and surgical teams
M. Cecilia Lansang and Guillermo E. Umpierrez
Advances in menopause transition management
Guest Editor
Andrew M. Kaunitz, MD
Authors
Sheryl Kingsberg, PhD; Michael Krychman, MD; Juliana M. Kling, MD, MPH; JoAnn E. Manson, MD, DrPH; James H. Liu, MD; Gretchen Collins, MD; Susan Kellogg Spadt, PhD, CRNP, IF, FCST, CSC
The object of this special issue is to enhance how you respond to and manage patients' menopausal and sexuality symptom concerns. The articles aim to alert women's health professionals to:
- the effects of sexual dysfunction, genitourinary syndrome of menopause in particular, on women emotionally and physically, and the available treatment options
- current nonhormonal treatment for hot flashes
- latest data on SERMs' role in managing menopausal symptoms, considering matching patients' symptoms to agents
- recommendations for intimacy counseling.
Articles included:
Not enough women are receiving treatment for bothersome menopausal symptoms
Andrew M. Kaunitz, MD
Mitigating the impact of genitourinary syndrome of menopause on sexuality
Sheryl Kingsberg, PhD, and Michael Krychman, MD
Nonhormonal treatment options for vasomotor symptoms of menopause
Juliana M. Kling, MD, MPH, and JoAnn E. Manson, MD, DrPH
SERMs in menopause: Matching agents to patients' symptoms and attributes
James H. Liu, MD, and Gretchen Collins, MD
Tips for counseling women about intimacy after menopause
Susan Kellogg Spadt, PhD, CRNP, IF, FCST, CSC
Guest Editor
Andrew M. Kaunitz, MD
Authors
Sheryl Kingsberg, PhD; Michael Krychman, MD; Juliana M. Kling, MD, MPH; JoAnn E. Manson, MD, DrPH; James H. Liu, MD; Gretchen Collins, MD; Susan Kellogg Spadt, PhD, CRNP, IF, FCST, CSC
The object of this special issue is to enhance how you respond to and manage patients' menopausal and sexuality symptom concerns. The articles aim to alert women's health professionals to:
- the effects of sexual dysfunction, genitourinary syndrome of menopause in particular, on women emotionally and physically, and the available treatment options
- current nonhormonal treatment for hot flashes
- latest data on SERMs' role in managing menopausal symptoms, considering matching patients' symptoms to agents
- recommendations for intimacy counseling.
Articles included:
Not enough women are receiving treatment for bothersome menopausal symptoms
Andrew M. Kaunitz, MD
Mitigating the impact of genitourinary syndrome of menopause on sexuality
Sheryl Kingsberg, PhD, and Michael Krychman, MD
Nonhormonal treatment options for vasomotor symptoms of menopause
Juliana M. Kling, MD, MPH, and JoAnn E. Manson, MD, DrPH
SERMs in menopause: Matching agents to patients' symptoms and attributes
James H. Liu, MD, and Gretchen Collins, MD
Tips for counseling women about intimacy after menopause
Susan Kellogg Spadt, PhD, CRNP, IF, FCST, CSC
Guest Editor
Andrew M. Kaunitz, MD
Authors
Sheryl Kingsberg, PhD; Michael Krychman, MD; Juliana M. Kling, MD, MPH; JoAnn E. Manson, MD, DrPH; James H. Liu, MD; Gretchen Collins, MD; Susan Kellogg Spadt, PhD, CRNP, IF, FCST, CSC
The object of this special issue is to enhance how you respond to and manage patients' menopausal and sexuality symptom concerns. The articles aim to alert women's health professionals to:
- the effects of sexual dysfunction, genitourinary syndrome of menopause in particular, on women emotionally and physically, and the available treatment options
- current nonhormonal treatment for hot flashes
- latest data on SERMs' role in managing menopausal symptoms, considering matching patients' symptoms to agents
- recommendations for intimacy counseling.
Articles included:
Not enough women are receiving treatment for bothersome menopausal symptoms
Andrew M. Kaunitz, MD
Mitigating the impact of genitourinary syndrome of menopause on sexuality
Sheryl Kingsberg, PhD, and Michael Krychman, MD
Nonhormonal treatment options for vasomotor symptoms of menopause
Juliana M. Kling, MD, MPH, and JoAnn E. Manson, MD, DrPH
SERMs in menopause: Matching agents to patients' symptoms and attributes
James H. Liu, MD, and Gretchen Collins, MD
Tips for counseling women about intimacy after menopause
Susan Kellogg Spadt, PhD, CRNP, IF, FCST, CSC
Targeting T and B Cells as a Therapeutic Approach for Multiple Sclerosis
Immunotherapies that target abnormally activated T and B cells may represent a unique combination and promising DMT strategy for patients with RRMS and have the greatest potential for long-term success. Targeting T cells in MS may help attenuate initiation and maintenance of inflammatory attacks by reducing the production of pro-inflammatory cytokines, recruitment of innate immune cells, stimulation of antibody production, and direct attack of myelin. Targeting B cells in MS may attenuate secretion of autoantibodies and pro-inflammatory cytokines, as well as presentation of self-antigen to T cells.
Click here to read the digital edition.
Immunotherapies that target abnormally activated T and B cells may represent a unique combination and promising DMT strategy for patients with RRMS and have the greatest potential for long-term success. Targeting T cells in MS may help attenuate initiation and maintenance of inflammatory attacks by reducing the production of pro-inflammatory cytokines, recruitment of innate immune cells, stimulation of antibody production, and direct attack of myelin. Targeting B cells in MS may attenuate secretion of autoantibodies and pro-inflammatory cytokines, as well as presentation of self-antigen to T cells.
Click here to read the digital edition.
Immunotherapies that target abnormally activated T and B cells may represent a unique combination and promising DMT strategy for patients with RRMS and have the greatest potential for long-term success. Targeting T cells in MS may help attenuate initiation and maintenance of inflammatory attacks by reducing the production of pro-inflammatory cytokines, recruitment of innate immune cells, stimulation of antibody production, and direct attack of myelin. Targeting B cells in MS may attenuate secretion of autoantibodies and pro-inflammatory cytokines, as well as presentation of self-antigen to T cells.
Click here to read the digital edition.
Pathophysiology of Type 2 Diabetes: The Evolution of Our Understanding
Update on Guidelines and Technology in the Diagnosis and Treatment of Trichomonas vaginalis
The Centers for Disease Control and Prevention (CDC) published an update to the Sexually Transmitted Diseases Treatment Guidelines in June 2015. This supplement covers the specific changes related to the diagnosis and treatment of Trichomonas vaginalis infection.
Click here to download the PDF.
Sharon L. Hillier, PhD
Professor
Departments of Obstetrics, Gynecology and
Reproductive Sciences and Microbiology
and Molecular Genetics
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Claire Danby, MD, MSc
Assistant Professor
Tufts University School of Medicine
Boston, Massachusetts
Department of Obstetrics and Gynecology
Maine Medical Center
Portland, Maine
Paul Nyirjesy, MD
Professor
Departments of Obstetrics and Gynecology and Medicine
Director, Drexel Vaginitis Center
Drexel University College of Medicine
Philadelphia, Pennsylvania
Maria Trent, MD, MPH
Associate Professor of Pediatrics
Division of General Pediatrics and Adolescent Medicine
Johns Hopkins School of Medicine
Baltimore, Maryland
Disclosures: Dr. Hillier reports that she is a consultant to Perrigo and Symbiomix and has an ongoing relationship with Becton Dickinson, Cepheid, and Hologic. Dr. Danby reports no financial relationships relevant to this article. Dr. Nyirjesy reports that he is a consultant to Hologic and has received a research grant from Becton Dickinson. Dr. Trent reports that she is the Principal Investigator of an unrestricted research grant to Johns Hopkins University (employer) from Hologic, Inc.
The Centers for Disease Control and Prevention (CDC) published an update to the Sexually Transmitted Diseases Treatment Guidelines in June 2015. This supplement covers the specific changes related to the diagnosis and treatment of Trichomonas vaginalis infection.
Click here to download the PDF.
Sharon L. Hillier, PhD
Professor
Departments of Obstetrics, Gynecology and
Reproductive Sciences and Microbiology
and Molecular Genetics
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Claire Danby, MD, MSc
Assistant Professor
Tufts University School of Medicine
Boston, Massachusetts
Department of Obstetrics and Gynecology
Maine Medical Center
Portland, Maine
Paul Nyirjesy, MD
Professor
Departments of Obstetrics and Gynecology and Medicine
Director, Drexel Vaginitis Center
Drexel University College of Medicine
Philadelphia, Pennsylvania
Maria Trent, MD, MPH
Associate Professor of Pediatrics
Division of General Pediatrics and Adolescent Medicine
Johns Hopkins School of Medicine
Baltimore, Maryland
Disclosures: Dr. Hillier reports that she is a consultant to Perrigo and Symbiomix and has an ongoing relationship with Becton Dickinson, Cepheid, and Hologic. Dr. Danby reports no financial relationships relevant to this article. Dr. Nyirjesy reports that he is a consultant to Hologic and has received a research grant from Becton Dickinson. Dr. Trent reports that she is the Principal Investigator of an unrestricted research grant to Johns Hopkins University (employer) from Hologic, Inc.
The Centers for Disease Control and Prevention (CDC) published an update to the Sexually Transmitted Diseases Treatment Guidelines in June 2015. This supplement covers the specific changes related to the diagnosis and treatment of Trichomonas vaginalis infection.
Click here to download the PDF.
Sharon L. Hillier, PhD
Professor
Departments of Obstetrics, Gynecology and
Reproductive Sciences and Microbiology
and Molecular Genetics
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Claire Danby, MD, MSc
Assistant Professor
Tufts University School of Medicine
Boston, Massachusetts
Department of Obstetrics and Gynecology
Maine Medical Center
Portland, Maine
Paul Nyirjesy, MD
Professor
Departments of Obstetrics and Gynecology and Medicine
Director, Drexel Vaginitis Center
Drexel University College of Medicine
Philadelphia, Pennsylvania
Maria Trent, MD, MPH
Associate Professor of Pediatrics
Division of General Pediatrics and Adolescent Medicine
Johns Hopkins School of Medicine
Baltimore, Maryland
Disclosures: Dr. Hillier reports that she is a consultant to Perrigo and Symbiomix and has an ongoing relationship with Becton Dickinson, Cepheid, and Hologic. Dr. Danby reports no financial relationships relevant to this article. Dr. Nyirjesy reports that he is a consultant to Hologic and has received a research grant from Becton Dickinson. Dr. Trent reports that she is the Principal Investigator of an unrestricted research grant to Johns Hopkins University (employer) from Hologic, Inc.
Highlights From the SCNS Meeting
Click here to download the digital edition.
Click here to download the digital edition.
Click here to download the digital edition.
Rare Neurological Disease Special Report
Click here to visit the digital edition.
Click here to visit the digital edition.
Click here to visit the digital edition.
